LY2228820 + Carboplatin + Placebo + Gemcitabine

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Epithelial Ovarian Cancer

Conditions

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Trial Timeline

Jul 1, 2012 → May 11, 2018

NCT ID

NCT01663857

About LY2228820 + Carboplatin + Placebo + Gemcitabine

LY2228820 + Carboplatin + Placebo + Gemcitabine is a phase 1/2 stage product being developed by Eli Lilly for Epithelial Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01663857. Target conditions include Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01663857	Phase 1/2	Completed	Jul 1, 2012	May 11, 2018	Epithelial Ovarian Cancer

Competing Products

20 competing products in Epithelial Ovarian Cancer

See all competitors

Product	Company	Stage	Hype Score
gemcitabine + carboplatin + paclitaxel	Eli Lilly	Phase 2	52
Pemetrexed	Eli Lilly	Phase 2	52
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution	Santen Pharmaceutical	Phase 2	52
Mirvetuximab Soravtansine + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin	AbbVie	Phase 3	77
Carboplatin + Mirvetuximab Soravtansine + Bevacizumab	AbbVie	Phase 2	52
Mirvetuximab Soravtansine	AbbVie	Phase 2	52
AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + Topotecan	AstraZeneca	Phase 3	77
Avelumab	AstraZeneca	Phase 2	52
Active Comparator: Olaparib tablets + Placebo	AstraZeneca	Phase 3	77
Olaparib + carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly	AstraZeneca	Phase 2	52
Olaparib + Bevacizumab	AstraZeneca	Approved	85
Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™	Merck	Phase 3	77
Pembrolizumab	Merck	Phase 2	52
MK-1775 and carboplatin	Merck	Phase 2	52
Gardasil	Merck	Phase 1	33
NG-350A plus Pembrolizumab	Merck	Phase 1	33
Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)	Merck	Phase 3	77
V501	Merck	Phase 3	77
9-valent HPV vaccination	Merck	Phase 2	52
Human Papillomavirus vaccine	Merck	Phase 2	52

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved